Hi [[ session.user.profile.firstName ]]

Forensic Science

  • A unique Q&A session/open forum panel debate.

    It is likely that you interact with ‘the cloud’ on various devices, multiple times throughout the day. However, for pharma we have only just scratched the surface regarding what the cloud can offer in terms of security, connectivity and efficacy. ‘Business analytics’ and ‘cloud’ are often misunderstood.

    To answer this, pharmaphorum, in conjunction with industry stalwarts Equinix, present a unique Q&A event, offering the opportunity to ask any questions you may have around what the cloud can do, and how to remain compliant in utilising this technology.

    This debate is an open forum and the expert panel will offer insight about interaction between the cloud and pharma with a particular focus on:
    • Patient outcomes – The cloud and patients, what are the routes to improving outcomes?
    • Internet of things – As the ways to gather data and interact increase exponentially, how does the cloud support this? What are the opportunities and can we eliminate the risk?
    • Data and security – How to achieve compliance almost automatically.
    • Collaboration – Why and how the cloud enables true partnership working.
  • Key Learning Objectives

    - Get an introduction to Six Sigma metrics
    - Learn what Six Sigma metrics are and how can they help the laboratory
    - See how laboratory tests perform on a Six Sigma scale
    - Learn about assessment tools for quality control strategy
  • There are clear benefits for both Life Sciences companies and their customers in significantly improving the way they engage. Be it in terms of reputation, efficiency, profitability, or even relationship quality and longevity, engagement has and will always be the key to successful business practice.

    Recent exclusive research conducted in conjunction with Zephyr Health revealed that both frontline sales forces and sales management professionals want to improve engagement strategies with new technology utilizing predictive insights. However, despite having new tools available to them, sales teams remain heavily reliant on the same techniques that were being used decades ago.

    So what is the answer – how do life sciences companies disrupt this pattern and make significant strides to improve engagement?

    Working with Zephyr Health, we present an expert webinar that will answer this very question, bringing together industry experts to discuss why the disruption is critical, how it can be achieved, and the core role that predictive insights play in this process.

    As with all of our webcasts, this is an interactive debate designed to enable you to get the answers you need.

    Topics covered include:

    •Customer engagement challenges and trends: the need for disruptive customer engagement – what the survey revealed
    •The challenges facing Life Sciences customer engagement
    •Why technology is only partially solving the problem
    •The evolution of CRM: from historic analytics to current analytics to future analytics – knowing what your customer wants before they do
    •Overcoming internal blockers to change within Life Sciences – the roadmap for success
  • This webinar will provide you with an overview how digital can be integrated into medical plans and what it takes to deliver multichannel medical excellence at launch.

    Key topics include:
    •Overview of typical launch categories and their key communication drivers and multichannel opportunities
    •The 4 main pre-launch stakeholders and how to integrate digital initiatives in a balanced medical mix whilst respecting legal and regulatory guidelines
    oeKOLs: Gathering insight and engagement planning
    oeHCPs: Channel selection to ensure immersive learning and education
    oePatients: Gathering treatment insight and prepare education & value-focused “beyond the-pill” strategies for launch
    oePayers: Establish value
    •Assess the clinical impact of e-medical programmes and how to create KPIs and dashboards to assess the success of your cross-channel activities
    •Prepare your organization for emedical excellence through multichannel skills development and enablement for MSLs and internal staff
  • Meeting the needs of both patients, and healthcare professionals, in today's fast changing communications landscape can be challenging, particularly against the backdrop of compliance. Putting creativity at the heart of the process can be the most effective way of tackling these challenges.

    Although the return on investment of creativity is not always easy to measure, the value it can bring to pharma and healthcare is increasingly evident.

    This webinar brings together a wealth of expertise to deliver case-study based evidence, interactive debate and practical advice on deriving competitive advantage from the creative process and ensuring patients are truly at the heart of your business.
  • PASSWORD: LightStrike -- Join this webinar to become an instant expert in xenon light room disinfection. Hear the latest evidence-based best practices for optimizing the use of Xenex Germ-Zapping Robots to tackle C. diff, MRSA and other difficult pathogens that linger in hospitals and post-acute care units.

    Hospitals across the country continue to publish infection rate reductions achieved using pulsed xenon light disinfection technology. Dr. Mark Stibich, Xenex Founder and Chief Scientific Officer, will discuss the published outcome studies to date and share best practices to help you reduce the risk of infection in your facility.
  • PASSWORD: LightStrike -- Join this webinar to become an instant expert in xenon light room disinfection. Hear the latest evidence-based best practices for optimizing the use of Xenex Germ-Zapping Robots to tackle C. diff, MRSA and other difficult pathogens that linger in hospitals and post-acute care units.

    Hospitals across the country continue to publish infection rate reductions achieved using pulsed xenon light disinfection technology. Dr. Mark Stibich, Xenex Founder and Chief Scientific Officer, will discuss the published outcome studies to date and share best practices to help you reduce the risk of infection in your facility.
  • Learn how Beckman Coulter’s hematology and laboratory automation technologies have helped standardize procedures, deliver consistent turnaround time, reduce manual intervention, and achieve high auto validation rates. Alan Neal will share how his laboratory implemented Beckman Coulter automation and LEAN manufacturing principles.
  • •Are you looking to deliver your research within Europe?
    •Do you need multiple, reliable sites and experienced investigators?
    •Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that has all changed with the Department of Health’s investment in the clinical research network infrastructure in the UK.

    Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical Company, Contract Research Organisation, Biotech, Med Tech or Diagnostic company we can help.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Dr Matt Cooper, Business Development and Marketing Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for running clinical research studies.

    You can discover:
    •How much the UK’s market volume of commercial contract research has grown and how we recruited over 34,000 patients to commercial clinical trials in 2014/15
    •What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    •The free feasibility service run by the NIHR CRN
    •How to gain access to our experienced clinical experts
    •How we are keeping clinical research in the public eye
    •How the UK is sharpening its competitive edge by achieving more key first global patients

    The NIHR CRN is exhibiting at the BioPharma Asia Convention 2016, visit stand B22 from 22-24 March to find out more about what we do to support clinical research and how we can help you deliver your studies in the UK.
  • CRISPR Cas9 nucleases have revolutionized the field of genome editing enabling unprecedented efficiency of gene targeting in a vast array of cell types and organisms. Even with such powerful technology at hand, researchers who are new to the field may find genome modification to be challenging and time-consuming. As CRISPR becomes a focus of the molecular biology research community, MilliporeSigma seeks to share the best approaches learned and methods applied in our years of genome editing experience. Today’s presentation will focus on practical applications of CRISPR for pristine genome editing to achieve knockout as well as specific sequence changes to include donor-mediated snps, reporter-tags and conditional knockouts. Special attention will be paid to design considerations for the donor constructs necessary to achieve specific sequence changes. Finally, the frontiers of CRISPR technology, including synthetic crRNA to fast-track genome editing experiments, whole genome screening and targeted gene activation will be explored.
  • According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.

    As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous. As important as what we are saying and where these conversations are taking place may be, it is only part of the conundrum. Developing, maintaining and managing content is a continuous challenge, made all the more taxing not only by strict internal deadlines but the cultural, linguistic and regulatory challenges that go hand in hand with managing global communications.

    Working with our expert partner SDL , we present a live webinar which will deliver insight and guidance on this topic, look in depth at one of the more traditional areas of patient liaison – trial recruitment – and bring you advice from the ‘frontline’ on what works in tackling these content challenges.

    On this latest live webinar, we’ll be discussing:
    •How to develop patient-centric recruitment content that REALLY communicates
    •Best practices of how to handle the linguistic, cultural and regulatory challenges often faced with creating multilingual patient-centric content
    •How simple content management best practices can help you become more patient centric with your content
    •Recent case studies: we’ll be discussing recent successes of global pharmaceutical businesses that have optimised and streamlined recruitment processes with relevant, accurate content development in the right language.
  • The new EPA METHOD 325 for sampling Volatile Organic Compounds from Fugitive and Area Sources was promulgated in September of 2015. The petroleum refineries have 2 years to comply with the new ruling. Benzene emissions are the focus of the new ruling, but other VOC’s can be monitored using the same sampling tube. The air samples are collected using thermal desorption tubes that are deployed along fenceline of the property and remain deployed for 14 days. The samples are collected passively, without the using of an air sampling pump. After sampling the diffusive endcap is replaced with a metal storage cap and sent to a laboratory where they’re analyzed by thermal desorption gas chromatography. This is the first of a two series presentation that focuses on the analysis side of the workflow. It provides users the steps required to comply with the new EPA fence line regulations and what is needed to optimize the method for high sample throughput. Refineries and testing laboratories will benefit by gaining valuable information on the optimum techniques to perform this method and what it takes to comply. An introduction to the theory and operation of thermal desorption will also be included.
  • Key topics to be discussed during the webinar:

    1)The paradox in Pharma
    2)HCPs expectations and behaviours
    3)Pharma Digital Maturity
    4)The Orchestrator rep
    5)How to implement?
  • Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
  • Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
  • The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series.

    While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology. Within the changing landscape of drug development, payers need robust evidence in order to accurately assess the value and efficacy of innovative treatments for both smaller patient populations and increasingly expensive medicines. Answering this paradigm is where real world evidence can step in.
    Topics covered include:
    •The HTA landscape – the challenges of assessing rare disease and cancer medicines
    •How regulators consider RWE in HTAs
    •Learnings from best practice in global markets
    •Recent case studies – successes and failures
    •The role of the regulator in the Cancer Drugs Fund
    •How RWE can assist market access
  • A Canadian, government backed, student organization specifically formed to research and complete 3d Printed Projects
  • CELLINK is the final puzzle piece in the 3D Bioprinting industry we all have been waiting for. CELLINK is a bioink that can universally be used on a wide range of 3D Bioprinters. CELLINK can also be used independently of any printing device, in case you want to perform simpler experiments of 3D cell culturing. The unique biocompatibility and printability of our bioink offers outstanding results that will take your research to the next level!
  • Our laboratory engineers microenvironments to control the fate of cells being used in tissue repair, with the main application being cartilage lesions and microcracks. The approaches include the development of patterned, functionalized hydrogels, mediation of cell-cell and cell-tissue adhesion through nano-coatings and surface treatment, control of inflammation and oxygen tension pathways, and release of cytoskeletal- and Rho GTPase-modifying small molecules to achieve stable phenotypes. Using additive manufacturing (bioprinting), it is possible to combine these tools to generate spatially complex tissues containing multiple cell types and materials. Our goal is the translation of these technologies to the clinics to improve the outcome of current cell-based therapies.
  • Jon Schull Phd from Rochester Institute of Technology will talk about founding the "Enable Organization", a global network of Passionate Volunteers Using 3d Printing to give prosthetic hands to the Underserved Populations of the World
  • Jean-Manuel brings more than 20 years of experience in scientific research and medical technology innovation to his work on the Vizua team. While earning his masters degree in neuroscience at Drexel Medical School in Philadelphia, he directed research projects on 3D-reconstruction of neuronal networks and regenerative quantification.
  • Dr. Baena a bioprinting and orthopedic industry professional. He is founder and CEO of BRECA Health Care and REGEMAT 3D. His work includes professional biomedical engineering and biomechanics, 3D bioprinting, medical devices development, CAD, CFD, FE, creating mathematical models to simulate complex environments and make decisions - Using technology to improve people´s quality of life.
    Linked in:
  • Dr. Shanjani has extensive research experience in system design and development, modeling, testing and utilizing 3D-printing and bioprinting technologies, hardware and software for biomedical, tissue engineering and regenerative medicine applications. He will speak about how 3D printing can be applied to regenerative orthopedics.
  • The Ourobotics Revolution 3D Bioprinter, is a relatively low-cost machine that can print with 10 materials in the same bioprinted structure (with the potential to add even more). It also includes a heated enclosure and an upgradable and expandable design. Because of its modularity, current applications include everything from human tissue engineering, to pharmaceuticals, food, synthetic biology, electronics, batteries and even textiles.